Clinical Context
Paroxysmal supraventricular tachycardia (PSVT) is characterized by episodes of abnormally fast heart rhythms, often exceeding 100 beats per minute. These episodes can lead to symptoms such as palpitations, dizziness, chest discomfort, and shortness of breath. Current treatment for acute PSVT typically requires emergency department visits and intravenous adenosine, which can cause adverse reactions. Oral medications take longer to act, often requiring 2 to 3 hours to achieve peak serum levels, which is insufficient for patients with severe symptoms. The recent FDA approval of etripamil (Cardamyst) addresses this gap by providing a fast-acting, self-administered nasal spray option for patients experiencing PSVT episodes.
Q: What is etripamil (Cardamyst) approved for?
A: Etripamil is approved for the outpatient treatment of paroxysmal supraventricular tachycardia (PSVT) episodes, allowing rapid conversion to sinus rhythm. The FDA approved etripamil on December 12, 2025, based on the RAPID trial which demonstrated significant efficacy in restoring normal heart rhythm [1].
Q: How does etripamil work?
A: Etripamil is a calcium channel blocker that acts quickly to restore normal heart rhythm during episodes of PSVT. It is self-administered as a nasal spray, providing a rapid alternative to traditional treatments that require intravenous administration [1].
Q: What is the recommended dose of etripamil?
A: The recommended dose of etripamil is 70 mg, administered as a nasal spray in each nostril. Clinicians should consult current prescribing information for full dosing guidance. If symptoms persist after 10 minutes, a second dose may be taken [1].
Q: What are the most common side effects of etripamil?
A: The most common side effects include nasal discomfort, nasal congestion, runny nose, throat irritation, and nosebleeds. Patients with hypersensitivity to etripamil or certain pre-existing conditions should avoid its use [1].